Silence Therapeutics to Participate in Three September Investor Conferences

Investors can watch live webcasts and later view archived replays of Silence Therapeutics’ September conference fireside chats on the company website.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast.

• Cantor Global Healthcare Conference 2026
  Fireside chat on Wednesday, September 9, 2026 at 10:55 a.m. ET

• H.C. Wainwright 28th Annual Global Investment Conference
  Fireside chat on Tuesday, September 15, 2026 at 3:00 p.m. ET

• Morgan Stanley 24th Annual Global Healthcare Conference
  Fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. ET

The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com/events. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902345520/en/

Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc

Key Terms

sirna medical

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.